-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I0Ku2nrluXhSmmtB2as+hYIJSXyGgCKza1VgQ+Rx8BVwN8GsXB9mA/oZe858NRF2 abqNKRaTmkszGFIujpK6TQ== 0000898432-97-000525.txt : 19971219 0000898432-97-000525.hdr.sgml : 19971219 ACCESSION NUMBER: 0000898432-97-000525 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19971218 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MGI PHARMA INC CENTRAL INDEX KEY: 0000702131 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411364647 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-33822 FILM NUMBER: 97740650 BUSINESS ADDRESS: STREET 1: 9900 BREN RD EAST STE 300E STREET 2: C/O OPUS CENTER MINNETONKA MINNESOTA CITY: MINNEAPOLIS STATE: MN ZIP: 55343 BUSINESS PHONE: 6129357335 MAIL ADDRESS: STREET 1: OPUS CENTER STREET 2: 9900 BREN ROAD EAST SUITE 300E CITY: MINNEAPOLIS STATE: MN ZIP: 55343 FORMER COMPANY: FORMER CONFORMED NAME: MOLECULAR GENETICS INC DATE OF NAME CHANGE: 19900812 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AVENIR CORP/DC CENTRAL INDEX KEY: 0001033475 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 541146619 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 1725 K STREET N W STREET 2: SUITE 410 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2026594427 SC 13G 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __)* MGI Pharma Inc. ----------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------- (Title of Class of Securities) 552880106 ---------------------------------- (CUSIP Number) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 5 pages CUSIP No. 552880106 13G Page 2 of 5 Pages 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Avenir Corporation IRS ID No.: 54-1146619 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /__/ (b) /X/ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION State of Virginia, United States 5 SOLE VOTING POWER NUMBER OF 762,680 SHARES 6 SHARED VOTING POWER 0 BENEFICIALLY OWNED BY 7 SOLE DISPOSITIVE POWER 762,680 EACH REPORTING PERSON 8 SHARED DISPOSITIVE POWER 0 WITH 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 762,680 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* N/A 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.41% 12 TYPE OF REPORTING PERSON* IA CUSIP No. 552880106 13G Page 3 of 5 Pages Item 1. (a) Name of Issuer MGI Pharma Inc. (b) Address of Issuer's Principal Executive Offices Opus Center 9900 Bren Road, East Suite 3003 Minneapolis, Minnesota 55343 Item 2. (a) Name of Person Filing Avenir Corporation (b) Address of Principal Business Office or, if none, Residence 1725 K Street, NW Ste 410 Washington, D.C. 20006 (c) Citizenship State of Virginia (d) Title of Class of Securities Common Stock (e) CUSIP Number 552880106 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a: (a) /__/ Broker or Dealer registered under Section 15 of the Act (b) /__/ Bank as defined in section 3(a)(6) of the Act (c) /__/ Insurance Company as defined in section 3(a)(19) of the act (d) /__/ Investment Company registered under section 8 of the Investment Company Act (e) /X_/ Investment Adviser registered under section 203 of the Investment Advisers Act of 1940 (f) /__/ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see 240.13d-l(b)(l)(ii)(F) (g) /__/ Parent Holding Company, in accordance with 240.13d-l(b)(ii)(G) (Note: See Item 7) CUSIP No. 552880106 13G Page 4 of 5 Pages (h) /__/ Group, in accordance with 240.13d-l(b)(l)(ii)(H) Item 4. Ownership If the percent of the class owned, as of December 31 of the year covered by the statement, or as of the last day of any month described in Rule 13d-l(b)(2), if applicable, exceeds five percent, provide the following information as of that date and identify those shares which there is a right to acquire. (a) Amount Beneficially Owned 762,680 (b) Percent of Class 5.41% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote 762,680 (ii) shared power to vote or to direct the vote 0 (iii) sole power to dispose or to direct the dispostion of 762,680 (iv) shared power to dispose or to direct the disposition of 0 Item 5. Ownership of Five Percent or Less of a Class Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable Item 8. Identification and Classification of Members of the Group Not Applicable Item 9. Notice of Dissolution of Group Not Applicable CUSIP No. 552880106 13G Page 5 of 5 Pages Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. December 18, 1997 Avenir Corporation By: /s/ Charles G. Mackall, Jr. ---------------------------- Charles G. Mackall, Jr. President -----END PRIVACY-ENHANCED MESSAGE-----